Abstract: An electronic shipment planner is adapted for electronically presenting shipment and scheduling information to a user. The shipment and scheduling information includes at least one shipment event date. The shipment planner is linked to a shipment data repository containing shipment and scheduling information. A system interface communicates with the shipment data repository. An interactive shipment data link is electronically associated with the shipment and scheduling information, and cooperates with the system interface as commanded by the user to access and retrieve the associated shipment and scheduling information contained in the shipment data repository. A calendar display interface displays the shipment planner to the user in a calendar format, such that the interactive shipment data link is provided on the shipment event date associated with the shipment and scheduling information.

Abstract: Methods and materials are provided for integrating heterologous nucleic acids into the genome of a cell or virus without disrupting expression of genes adjacent to the insertion site.

Abstract: A metal fitting finding particular application as a corner fitting for an ISO freight container. The corner fitting is preferably cuboidal and comprises walls formed from a first material that define an internal cavity. At least one support member is encapsulated within the walls and is formed from a different material to that of the walls and comprises a greater yield strength. A reinforced corner fitting is therefore provided comprising enhanced load bearing capacity.

Abstract: An electronic user interface for use with a water delivery device, such as a faucet.

Abstract: A fluid delivery device including a valve body fluidly coupled to an electrically insulating waterway assembly. The waterway assembly may include a molded base.

Abstract: Methods and materials are provided for the production of compositions of erythropoietin protein, wherein said compositions comprise a pre-selected N-linked glycosylation pattern as the predominant N-glycoform.

Abstract: Compounds of formula (I): [where: R1 is a direct bond, oxygen, a group >CH2, sulphur, a group >C?O, a group —(CH2)2— or a group-N-Ra, where Ra is hydrogen or alkyl; R3, R4, R5 and R6 are hydrogen or substituents ?; R8, R9, R10 and R11 are hydrogen, hydroxy or alkyl; or R9 and R11 are joined to form a fused ring system with the benzene rings to which they are attached; R7 is a direct bond, oxygen or a —CH2-group; p is 0 or 1; substituents ? are: alkyl, alkoxy, alkenyl, halogen, nitrile, hydroxyl, aryl, aralkyl, aryloxy, aralkyloxy, arylalkenyl, cycloalkyl, carboxy, carboxyalkoxy, alkoxycarbonyl, aryloxycarbonyl, alkylcarbonyloxy, alkanesulphonyl, arenesulphonyl, alkanoyl or arylcarbonyl; n is 1 to 12; R12 is hydrogen, methyl or ethyl; A is a group —[O(CHR13CHR14)a]y—, —[O(CH2)bCO]y—, or —[O(CH2)bCO](y?1)—[O(CHR13CHR14)a]—, where: one of R13 and R14 is hydrogen and the other is hydrogen, methyl or ethyl; a is 1 to 2; b is 4 to 5; Q is a residue of a polyhydroxy compound having from 2 to 6 hydroxy gro

Abstract: Compounds of formula (I): [where: the substituents R1 are individually selected from C1-C10 alkyl groups and optionally substituted benzyl groups; the substituents R2 are individually selected from alkyl groups or, together with the nitrogen atom to which they are attached, represent a nitrogen-containing heterocyclic group; Z is selected from C6-C10 arylene groups groups of formula —(CHR3)n—, where R3 is hydrogen, hydroxy or a C1-C4 alkyl group, and n is 0 to 6; Y is carbonyl or a residue of a mono- or poly-hydroxy compound; and x is 1 to 6; and esters thereof] are useful as multi-functional photoinitiators for use in coating compositions to be cured by radiant energy.

Abstract: A medicinal aerosol product and process, such as for an HFA metered dose inhaler, wherein at least one of the formulation ingredients is synthesized by running at least part of the chemical reaction to make the ingredient in a hydrofluoroalkane reaction medium.

Abstract: A method and apparatus for providing welding-type power includes a source of welding-type power and a controller. The controller is a state-based controller, and/or a deterministic control module, connected to the controller output. The state-based control module includes, in an embodiment, software instructions and a digital processor, and/or a state transition table stored in a spreadsheet data base. The controller is responsive to a feedback circuit. One or more welding peripherals, such as a wire feeder or robot, are connected to the controller. The current state may be represented by data in a first line of a spreadsheet and a state-ending event by a second, perpendicular, line of a spreadsheet. The subsequent state is determined by the intersection of the first and second lines in another embodiment.

Abstract: A medicant composition is provided. The composition includes a film layer and a powder matrix layer. The powder matrix layer includes a medicant. The powder matrix layer is applied to the film layer by admixing particulate to form a powder matrix and by then applying the powder matrix to the film layer by any desired method. The composition of the powder matrix is varied to alter the dissolution rate of the medicant, the adhesion of the medicant composition, and other physical properties of the powder matrix. The powder matrix layer can be cured.

Abstract: A viscous gel for delivering minor effective amounts of active substances through the nasal membrane into the body.

Abstract: A method and system for pulse welding provides an output pulse waveform. The waveform has at least a frequency from a range of available frequencies not limited to harmonic frequencies. The waveform provides power suitable for welding, and has a plurality of background portions alternating with a plurality of peak portions. A transition down occurs from the peak portion to the background portion with a first acceleration and a transition up occurs from the background portion to the peak portion with a second acceleration. At least one of the first and second accelerations are non-zero over at least most of the transition. The waveform is preferably created by switching an inverter. Both accelerations may be non-zero, and each transition may have two accelerations, one negative closer to the peak, and one positive closer to the background. The accelerations may be constant with opposite polarity. Preferably the process is current controlled during the transitions. The process frequency may be fixed or varying.

Abstract: Zirconia particles, methods of making zirconia particles, composite materials that contain the zirconia particles, methods of making the composite materials, and zirconia sols that contain the zirconia particles are described. The zirconia particles are substantially non-associated and have an average size no greater than 50 nanometers and may contain yttrium. The zirconia particles are prepared by a method that includes two separate hydrothermal treatments.

Abstract: A method and apparatus for welding is disclosed. The output is preferably a cyclical CV MIG output, and each cycle is divided into segments. An output parameter is sampled a plurality of times within one or more of the segments. The CV output is controlled within the at least one segment in response to the sampling. The parameter is output power, a resistance of the load, an output current, an output voltage, or functions thereof in various embodiments. The control loop is preferably a PI or PID loop. The loop may be applied only within a window. The set point may be taught or fixed. The system can be used to weld with a controlled arc length.

Abstract: The present invention relates to eukaryotic host cells, especially lower eukaryotic host cells, having modified oligosaccharides which may be modified further by heterologous expression of a set of glycosyltransferases, sugar and sugar nucleotide transporters to become host-strains for the production of mammalian, e.g., human therapeutic glycoproteins. The process provides an engineered host cell which can be used to express and target any desirable gene(s) involved in glycosylation. Host cells with modified lipid-linked oligosaccharides are created or selected. N-glycans made in the engineered host cells exhibit GnTIII, GnTIV, GnTV, GnT VI or GnTIX activity, which produce bisected and/or multiantennary N-glycan structures and may be modified further by heterologous expression of one or more enzymes, e.g., glycosyltransferases, sugar, sugar nucleotide transporters, to yield human-like glycoproteins.

Abstract: An antiglare device comprises a housing for coupling to a headlight of a vehicle. Surfaces of the housing which face a passenger side of the vehicle are reflective to encourage reflection of light away from oncoming traffic while surfaces of the housing facing towards the driver side of the vehicle are preferably non-reflective to reduce the amount of light reflected towards oncoming traffic. Plates may be supported within the housing through which the light passes in which the plates similarly include reflective and non-reflective surface. The plates may be pivotal between a high beam position parallel to the direction of light projected through the housing and a low beam position in which the plates are deflected in the direction in which the reflective surfaces face towards the passenger side so that light is encouraged to be deflected laterally away from the oncoming traffic by the plates.. The plates may instead be horizontal in the high beam position and deflected downwardly in the low beam positions.

Abstract: Compounds of formula (I): [where: R1 is a direct bond, oxygen, a group >CH2, sulphur, a group >C?O, a group-(CH2)2— or a group-N—Ra, where Ra is hydrogen or alkyl; R3, R4, R5 and R6 are hydrogen or substituents?; R8, R9, R10 and R11 are hydrogen, hydroxy or alkyl; or R9 and R11 are joined to form a fused ring system with the benzene rings to which they are attached; R7 is a direct bond, oxygen ora —CH2-group; p is 0 or 1 ; substituents? are: alkyl, alkoxy, alkenyl, halogen, nitrile, hydroxyl, aryl, aralkyl, aryloxy, aralkyloxy, arylalkenyl, cycloalkyl, carboxy, carboxyalkoxy, alkoxycarbonyl, aryloxycarbonyl, alkylcarbonyloxy, alkanesulphonyl, arenesulphonyl, alkanoyl or arylcarbonyl; n is 1 to 12; R12 is hydrogen, methyl or ethyl; A is a group —[O(CHR13CHR14)a]y—, —[O(CH2)bC0]y-, or —[O(CH2)bC0](y-1)-[O(CHR13CHR14)a]—, where: one of R13 and R14 is hydrogen and the other is hydrogen, methyl or ethyl; a is 1 to 2 ; b is 4 to 5 ; Q is a residue of a polyhydroxy compound having from 2 to 6 hydroxy groups; x

Abstract: Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use are disclosed.